Discovery of Novel Acyl Coenzyme A: Cholesterol Acyltransferase Inhibitors: Pharmacophore-Based Virtual Screening, Synthesis and Pharmacology

Chemical Biology and Drug Design

Volumn 80, Issue 1, 2012, Pages 106-113

  Chhabria, Mahesh T ^a   Brahmkshatriya, Pathik S ^a   Mahajan, Bhushan M ^a   Darji, Urvesh B ^a   Shah, Gaurang B ^b  

^a L M COLLEGE OF PHARMACY   (India)

^b K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

ACAT inhibitors; Cost analysis; Predictive pharmacophore; Validation; Virtual screening

Indexed keywords

CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; ETHYL 3,5 DIBROMO 4 [[[2 (PHENYLCARBONYL)PHENYL]CARBONYL]OXY]BENZOATE; ETHYL 3,5 DICHLORO 4 [[[2 (PHENYLCARBONYL)PHENYL]CARBONYL]OXY]BENZOATE; LIGAND; UNCLASSIFIED DRUG;

ARTICLE; COST BENEFIT ANALYSIS; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; IC 50; PHARMACOPHORE; PRIORITY JOURNAL;

ACYL COENZYME A; ANIMALS; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; MALE; MICROSOMES, LIVER; MODELS, MOLECULAR; RATS; STEROL O-ACYLTRANSFERASE;

EID: 84862149887     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01384.x     Document Type: Article

References (37)

1. Chhabria M.T., Brahmkshatriya P.S. (2006) Novel targets for the treatment of atherosclerosis. Curr Opin Invest Drugs;7:820-825.
2. Brahmkshatriya P.S., Chhabria M.T., Jani M.H. (2006) Recent developments in the treatment of atherosclerosis. J Enzyme Inhib Med Chem;21:1-15.
3. Kushwaha R.S., Vandeberg J.F., Rodriguez R., Vandeberg J.L. (2004) Cholesterol absorption and hepatic acyl-coenzyme A:cholesterol acyltransferase activity play major roles in lipemic response to dietary cholesterol and fat in laboratory opossums. Metabolism;53:817-822.
4. Rudel L.L., Lee R.G., Cockman T.L. (2001) Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr Opin Lipidol;12:121-127.
5. Field F.J., Salome R.G. (1982) Effect of dietary fat saturation, cholesterol and cholestyramine on acyl-CoA: cholesterol acyltransferase activity in rabbit intestinal microsomes. Biochim Biophys Acta;712:557-570.
6. Heider J.G., Pickens C.E., Kelly L.A. (1983) Role of acyl CoA:cholesterol acyltransferase in cholesterol absorption and its inhibition by 57-118 in the rabbit. J Lipid Res;24:1127-1134.
7. Drevon C.A., Engelhorn S.C., Steinberg D. (1980) Secretion of very low density lipoproteins enriched in cholesteryl esters by cultured rat hepatocytes during simulation of intracellular cholesterol esterification. J Lipid Res;21:1065-1071.
8. Khan B., Wilcox H.G., Heimberg M. (1989) Cholesterol is required for secretion of very-low-density lipoprotein by rat liver. Biochem J;258:807-816.
9. Cianflone K.M., Yasruel Z., Rodriguez M.A., Sniderman A.D. (1990) Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res;31:2045-2055.
10. Mishra R.K., Singh J. (2010) Generation, validation and utilizaiton of three-dimensional pharmacophore model for EP3 antagonists. J Chem Inf Model;50:1502-1509.
11. Brogi S., Kladi M., Vagias C., Papazafiri P., Roussis V., Tafi A. (2009) Pharmacophore modelling of qualitative prediction of antiestrogenic activity. J Chem Inf Model;49:2489-2497.
12. Krovat E.M., Langer T. (2003) Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem;46:716-726.
13. Funk O.F., Kettmann V., Drimal J., Langer T. (2004) Chemical function based pharmacophore generation of Endothelin-A selective receptor antagonists. J Med Chem;47:2750-2760.
14. Barreca M.L., Ferro S., Rao A., Luca L.D., Zappala M., Monforte A.-M., Debyser Z., Witvrouw M., Chimirri A. (2005) Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J Med Chem;48:7084-7088.
15. Chhabria M.T., Mahajan B.M., Brahmkshatriya P.S. (2010) QSAR study of a series of acyl coenzyme A (CoA): cholesterol acyltransferase inhibitors using genetic function approximation. Med Chem Res. Online first, DOI:.
16. Picard J.A., O'Brien P.M., Sliskovic D.R., Anderson M.K., Bousley R.F., Hemelehle K.L., Krause B.R., Stanfield R.L. (1996) Inhibitors of Acyl-CoA: cholesterol O-Acyltransferase. Structure-activity relationships of several series of compounds derived from N-chlorosulfonylisocyanate. J Med Chem;39:1243-1252.
17. O' Brien P.M., Sliskocic D.R., Picard J.A., Lee H.T., Purchase C.F., Roth B.D., White A.D. et al. (1996) Inhibitors of Acyl-CoA: cholesterol O-Acyltransferase. Synthesis and pharmacological activity of (±)-2-dodecyl-phenyl-N-(2, 4, 6, trimethoxy)-2H-tetrazole-5-acetamide and structurally related tetrazole amide derivatives. J Med Chem;39:2354-2366.
18. White A.D., Purchase C.F., Picard J.A., Anderson M.K., Mueller S.B., Bocan T.M.A., Bousley R.F., Hammelehle K.L., Krause B.R., Lee P., Stanfield R.L., Reindel J.F. (1996) Heterocyclic amides: inhibitors of Acyl-CoA:cholestrol O-Acyltransferase with hypocholesterolemic activity in several species and antiatherosclerotic activity in the rabbit. J Med Chem;39:3908-3919.
19. Sliskovic D.R., Picard J.A., O'Brien P.M., Liao P., Roark W.H., Roth B.D., Anderson M.A. et al. (1998) α-Substituted malonester amides: tools to define the relationship between ACAT inhibitors and adrenal toxicity. J Med Chem;41:682-690.
20. Giovannoni M.P., Piaz V.D., Kwon B.M., Kim Y.K., Toma L., Barlocco D., Bernini F., Canavesi M. (2001) 5-6-Diphenylpyridazine derivatives as Acyl- CoA:cholesterol acyltransferase inhibitors. J Med Chem;44:4292-4295.
21. Ohishi K., Aiyama R., Hatano H., Yoshida Y., Wada Y., Yokai W., Sawada H., Watanabe T., Yokokura T. (2001) Strucure-activity relationships of N-(3, 5-dimethoxy-4-n-octyloxycinnamoyl)-N9-(3, 4-dimethylphenyl)piperazine and analogues as inhibitors of Acyl CoA:cholesterol O-Acyltransferase. Chem Pharm Bull;49:830-839.
22. Toma L., Giovannoni M.P., Vergelli C., Piaz V.D., Kwon B.M., Kim Y.K., Gelain A., Barlocco A. (2002) Novel 3-arylamino- and 3-cycloalkylamino 5, 6-diphenyl-pyridazines active as ACAT Inhibitors. Arch Pharm Pharm Med Chem;11:563-566.
23. Lee H.T. (1996) Sulphonate ACAT inhibitors. U. S. Patent 5, 510, 379, April, 23.
24. Lee H.T. (1997) Tetrazole Alkyl Amide ACAT Inhibitors. U. S. Patent 5, 646, 170. July, 8.
25. Dugar S. (1994) 1, 2-Disubstituted Ethyl Amides as Inhibitors of ACAT. WO94/06784, March, 31.
26. Lee H.T., Picard J.A., Sliskovic D.R. (1996) β-Carboxy Sulfonamide ACAT Inhibitors. U. S. Patent 5, 491, 170, February, 13.
27. Roark W.H. (2000) Phosphonamide ACAT inhibitors. U. S. Patent 6, 017, 905, January, 25.
28. O'Brien P.M., Sliskovic D.R. (1995) Amide tetrazole ACAT inhibitors. U. S. Patent 5, 461, 049, October, 24.
29. Higley C., Wilde R.G., Maduskuie T.P., Johnson A.L., Pennev P., Billheimer J.T., Robinson C.S., Gillies P.J., Wexler R.R. (1994) Acyl CoA:cholesterol Acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles. J Med Chem;37:3511-3522.
30. Dugar S., Clader J.W., Burrier R.E., Kogan T.P. (1993) N-Oleoyl-1, 2, 3, 4- tetrahydroquinolines as confomationally restricted inhibitors of Acyl-CoA: cholesterol Acyl Transferase (ACAT). Bioorg Med Chem Lett;3:571-576.
31. Boswell G.A., Li H.Y., Delucca I., Billheimer J.T., Drummond S., Gillies P.J., Robinson C. (1996) Novel 4, 4-bis(trifluoromethyl) imidazoles as stereospecific and orally active Acyl CoA: cholesterol Acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents. Bioorg Med Chem Lett;6:885-888.
32. Debnath A.K. (2002) Pharmacophore mapping of a series of 2, 4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J Med Chem;45:41-53.
33. Largis E., Wang C., BeVaries V., Schaffe F. (2004) CL277, 082; A novel inhibitor of ACAT catalysed cholesterol esterification and cholesterol absorption. J Lipid Res;45:396-401.
34. Furniss B.S., Hannaford A.J., Smith P.W.G., Tatchell A.R. (2006) Vogel's Textbook of Practical Organic Chemistry, 5th edn. London, UK: Pearson Publishing Corp.
35. Wang Y., Ai J., Wang Y., Chen Y., Wang L., Liu G., Geng M., Zhang A. (2011) Synthesis and c-Met kinase inhibition of 3, 5-disubstituted and 3, 5, 7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent. J Med Chem;54:2127-2142.
36. Manvar A., Malde A., Verma J., Virsodia V., Mishra A., Upadhyay K., Acharya H., Coutinho E., Shah A. (2008) Synthesis, anti-tubercular activity and 3D-QSAR study of coumarin-4-acetic acid benzylidene hydrazides. Eur J Med Chem;43:2395-2403.
37. Ghose A.K., Crippen G. (1986) Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships I. Partition coefficient as a measure of hydrophobicity. J Comp Chem;7:565-577.